EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Long-term outcome of Graves’ orbitopathy following treatment with sirolimus

Simone Comi, Giada Cosentino, Giulia Lanzolla, Francesca Menconi, Maria Novella Maglionico, Chiara Posarelli, Francesco Latrofa, Roberto Rocchi, Michele Figus, Ferruccio Santini, Michele Marinò

Journal of Endocrinological Investigation · 2024

DOI: 10.1007/s40618-024-02470-8 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Endocrinological Investigation, 2024. Verfasst von Simone Comi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy. Hauptthemen laut MEDLINE: Sirolimus, Immunosuppressive Agents, Methylprednisolone. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università di Pisa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Sirolimus was found to be associated with a better outcome of Graves’ orbitopathy (GO) at 24 weeks compared to methylprednisolone. We conducted a retrospective study to investigate its efficacy and safety over a longer period.

Methods

Data from 40 consecutive patients with moderate-to-severe, active GO, 20 treated with sirolimus and 20 with methylprednisolone, were collected. Primary outcome: overall outcome (composite evaluation) of GO at 48 weeks. Secondary outcomes: (1) GO outcome at 24 weeks, and, at 24 and 48 weeks: (2) outcome of single eye features; (3) quality of life (GO-QoL); (4) TSH-receptor antibodies; (5) GO relapse at 48 weeks; (6) adverse events.

Results

The overall GO outcome at 48 weeks did not differ between the two groups (responders: 55% vs 55%). At 24 weeks, prevalence of responders was greater in sirolimus group (65% vs 25%; P = 0.01). A reduction ≥ 1 point in clinical activity score (CAS) was more frequent in sirolimus patients at 24 (85% vs 40%; P = 0.005) and 48 weeks (75% vs 60%; P = 0.03). The proportion of GO-QoL responders (appearance subscale) at 24 weeks was greater in sirolimus group (62.5% vs 26.3%; P = 0.03). No difference was observed for the remaining outcome measures.

Conclusions

Treatment with sirolimus is followed by a greater overall response of GO compared with methylprednisolone at 24 weeks, but not at 48 weeks, when only CAS is affected. A more prolonged period of treatment may be required for a better outcome to be observed over a longer period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusImmunosuppressive AgentsMethylprednisoloneRetrospective StudiesHumansMaleFemaleAdultMiddle AgedAgedGraves Ophthalmopathy

Stichwörter der Autor:innen

Graves’ diseaseGraves’ orbitopathyRapamycinSirolimusThyroid autoimmunityThyroid eye disease

Substanzen

SirolimusImmunosuppressive AgentsMethylprednisolone

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
  • Department of Orthopaedic Surgery, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Surgical, Medical and Molecular Pathology, Ophthalmopathy Unit I, University of Pisa and University Hospital of Pisa, Via Paradisa 2, 56124, Pisa, Italy.
  • Department of Clinical and Experimental Medicine, Endocrinology Units, University of Pisa, Via Paradisa 2, 56124, Pisa, Italy. michele.marino@med.unipi.it.

Förderung

  • Università di Pisa

Zitieren

APA

Comi, S., Cosentino, G., Lanzolla, G., Menconi, F., Maglionico, M. N., Posarelli, C., Latrofa, F., Rocchi, R., Figus, M., Santini, F., & Marinò, M. (2024). Long-term outcome of Graves’ orbitopathy following treatment with sirolimus. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-024-02470-8

Vancouver

Comi S, Cosentino G, Lanzolla G, Menconi F, Maglionico MN, Posarelli C, et al. Long-term outcome of Graves’ orbitopathy following treatment with sirolimus. Journal of Endocrinological Investigation. 2024. doi:10.1007/s40618-024-02470-8

BibTeX
@article{Comi2024,
  author = {Comi, Simone and Cosentino, Giada and Lanzolla, Giulia and Menconi, Francesca and Maglionico, Maria Novella and Posarelli, Chiara and Latrofa, Francesco and Rocchi, Roberto and Figus, Michele and Santini, Ferruccio and Marinò, Michele},
  title = {Long-term outcome of Graves’ orbitopathy following treatment with sirolimus},
  journal = {Journal of Endocrinological Investigation},
  year = {2024},
  doi = {10.1007/s40618-024-02470-8}
}
Kostenlos starten →